

Declaration and Power of Attorney for Patent Application

特許出願宣言書および委任状

Japanese Language Declaration

私は下記発明者として以下の通り宣言します：

As a below named inventor, I hereby declare that:

私の住所、郵送先、および国籍は私の氏名の後に記載された通りです。

My residence, mailing address and citizenship are as stated next to my name.

下記名称の発明に関し請求範囲に記載され特許出願がされている発明内容につき、私が最初、最先かつ唯一の発明者（下記氏名が一つの場合）であるか、あるいは最初、最先かつ共同発明者（下記氏名が複数の場合）であると信じます。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which I claimed and for which a patent is sought on the invention entitled

NOVEL URACIL DERIVATIVES AND

MEDICINAL USE THEREOF

下記項目に x 印が付いている場合を除き、上記発明の明細書は本書に添付されます。

☐ 上記発明は米国出願番号あるいは PCT 国際出願番号 _____ (確認番号 _____) として _____ 年 _____ 月 _____ 日に提出され、
_____ 年 _____ 月 _____ 日に補正されました (該当する場合)。

the specification of which is attached hereto unless the following box is checked:

☒ was filed on March 18, 2005
as United States Application Number 10/528373
and was filed on September 17, 2003
as PCT International Application Number
PCT/JP03/11859 (Conf. No. _____)
and was amended on _____
(if applicable).

私は特許請求範囲を含み上述の補正で補正された前記明細書の内容を検討し、理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は連邦規則法典第 37 編 1 条 56 項に定義される特許性に肝要な情報について開示義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

Japanese Language Declaration

私は米国法典第 35 編 119 条(a)-(d)あるいは 365 条(b)に基づき特許あるいは発明者証書の下記外国出願、または 365 条(a)に基づき米国以外の少なくとも 1 ヶ国を指定した下記 PCT 外国出願についての外国優先権をここに主張するとともに、下記項目に x 印を付けることにより優先権を主張する出願以前の出願日を有する特許あるいは発明者証書の外国出願あるいは PCT 外国出願を示します。

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below, and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior foreign application(s)
外国での先行出願

Priority Claimed
優先権の主張

2002-274559

(Number)
(番号)

Japan

(Country)
(国名)

20/September/2002

(Day/Month/Year Filed)
(出願年月日)

Yes No
有り無し
☒

(Number)
(番号)

(Country)
(国名)

(Day/Month/Year Filed)
(出願年月日)

私は米国法典第 35 編 119 条(e)に基づき下記の米国仮特許の利益をここに主張します。

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は米国法典第 35 編 120 条に基づき下記米国特許出願、あるいは 365 条(c)に基づき米国を指定する下記 PCT 国際特許出願の利益をここに主張し、本特許出願内特許請求範囲の各項目の内容が米国法典第 35 編 112 条の最初の項に規定される方法により先行米国あるいは PCT 国際特許出願で開示されていない限りにおいて連邦規則法典第 37 編 1 条 56 項に定義される特許性に肝要で、先行特許出願の出願日から本特許出願の国内あるいは PCT の出願日までの間に入手された情報について開示義務があることを認めます。

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Status: patented, pending, abandoned)
(状態: 特許成立済、係属中、放棄済)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Status: patented, pending, abandoned)
(状態: 特許成立済、係属中、放棄済)

私は本宣言書内で私自身の知識に基づいてなされたすべての陳述が真実であり、情報および信ずるところに基づいてなされたすべての陳述が真実であると信じられていることをここに宣言し、さらに故意になされた虚偽の陳述等々は米国法典第 18 編 1001 条に基づき罰金あるいは拘禁または両方による処罰にあたり、またかような故意による虚偽の陳述はそれに基づく特許出願あるいは成立特許の有効性を危うくする可能性があることを認識した上でこれらの陳述をなしたことを宣言します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration

委任状：私は下記の米国特許商標局（USPTO）顧客番号のもとに記載される SUGHRUE MION 法律事務所のすべての弁護士を、同顧客番号のもとに記載される個々の弁護士は Sughrue Mion 法律事務所のための自由裁量に基づき変更され得ることを認識した上で、本特許出願の続きおよびそれに関わる特許商標局との業務を遂行する弁護士として指名し、本特許出願に関するすべての通信が同 USPTO 顧客番号のもとに提出された住所宛に送付されることを要請します。

POWER OF ATTORNEY: I hereby appoint all attorneys of SUGHRUE MION, PLLC who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.

23373

23373

PATENT TRADEMARK OFFICE

電話連絡は下記へ：（名前および電話番号）

SUGHRUE MION, PLLC
+1 (202) 293-7060

Direct Telephone Calls to: (name and telephone number)

SUGHRUE MION, PLLC
(202) 293-7060

唯一あるいは第一の発明者名	Full name of sole or first inventor Yoshiaki ISOBE	
発明者の署名	日付	Inventor's signature <i>Yoshiaki Isobe</i> Date April 28, 2005
住所	Residence Osaka, Japan	
国籍	Citizenship Japan	
郵送先	Mailing Address c/o SUMITOMO PHARMACEUTICALS CO., LTD. 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, Japan	
第二の共同発明者（該当する場合）	Full name of second joint inventor, if any Masanori TOBE	
第二発明者の署名	日付	Second inventor's signature <i>Masanori Tobe</i> Date April 28, 2005
住所	Residence Osaka, Japan	
国籍	Citizenship Japan	
郵送先	Mailing Address c/o SUMITOMO PHARMACEUTICALS CO., LTD. 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, Japan	

第三の共同発明者 (該当する場合)		Full name of third joint inventor, if any Yoshifumi INOUE	
第三発明者の署名	日付	Third inventor's signature <i>Yoshifumi Inoue</i>	Date April 28, 2005
住所	Residence Osaka, Japan		
国籍	Citizenship Japan		
郵送先	Mailing Address c/o SUMITOMO PHARMACEUTICALS CO., LTD. 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, Japan		
第四の共同発明者 (該当する場合)		Full name of fourth joint inventor, if any Masakazu ISOBE	
第四発明者の署名	日付	Fourth inventor's signature <i>Masakazu Isobe</i>	Date April 28, 2005
住所	Residence Osaka, Japan		
国籍	Citizenship Japan		
郵送先	Mailing Address c/o SUMITOMO PHARMACEUTICALS CO., LTD. 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, Japan		
第五の共同発明者 (該当する場合)		Full name of fifth joint inventor, if any	
第五発明者の署名	日付	Fifth inventor's signature	Date
住所	Residence		
国籍	Citizenship		
郵送先	Mailing Address		
第六の共同発明者 (該当する場合)		Full name of sixth joint inventor, if any	
第六発明者の署名	日付	Sixth inventor's signature	Date
住所	Residence		
国籍	Citizenship		
郵送先	Mailing Address		

ASSIGNMENT

As a below named inventor, I hereby declare that:

IN CONSIDERATION of the sum of One Dollar(\$1.00) or the equivalent thereof, and other good and valuable consideration paid to me citizen of Japan by SUMITOMO PHARMACEUTICALS COMPANY, LIMITED, a corporation organized under the laws of Japan, located at 2-8, Doshomachi-2-chome, Chuo-ku, Osaka, Japan, receipt of which is hereby acknowledged I do hereby sell and assign to said SUMITOMO PHARMACEUTICALS COMPANY, LIMITED, its successors and assigns, all my right, title and interest, in and for the United States of America, in and to

NOVEL URACIL DERIVATIVES AND MEDICINAL USE THEREOF

*U.S. Serial No.10/528373 filed on March 18, 2005
invented by me (if only one is named below) or us (if plural inventors are named below) and described in the application for United States Letters Patent therefor, executed on even date herewith,

and all United States Letters Patent which may be granted therefor, and all divisions, continuations and extensions thereof, the said interest being the entire ownership of the said Letters Patent when granted, to be held and enjoyed by said SUMITOMO PHARMACEUTICALS COMPANY, LIMITED, its successors, assigns or other legal representatives, to the full end of term for which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me or us if this assignment and sale had not been made;

And I hereby agree to sign and execute any further documents or instruments which may be necessary, lawful, and proper in the prosecution of the above-named application or in the preparation and prosecution of any continuing, continuation-in-part, substitute, divisional, renewal, reviewed or reissue applications or in any amendment, extension, or interference proceedings, or otherwise to secure the title thereto in said assignee;

And I do hereby authorize and request the Commissioner of Patents to issue said Letters Patent to said SUMITOMO PHARMACEUTICALS COMPANY, LIMITED.

Signed on the date(s) indicated aside signatures:

INVENTOR(S) (発明者フルネームサイン)	Date Signed (署名日)	WITNESSES (立会人サイン)
1) <u>Yoshiaki ISOBE</u> Yoshiaki ISOBE	<u>April 28, 2005</u>	<u>Ayumu Kurimoto</u>
2) <u>Masanori TOBE</u> Masanori TOBE	<u>April 28, 2005</u>	<u>Masahiro Takamura</u>
3) <u>Yoshifumi INOUE</u> Yoshifumi INOUE	<u>April 28, 2005</u>	<u>Masako Goshima</u>
4) <u>Masakazu ISOBE</u> Masakazu ISOBE	<u>April 28, 2005</u>	<u>Gakuzi Hoshino</u>
5) _____	_____	_____
6) _____	_____	_____
7) _____	_____	_____
8) _____	_____	_____
9) _____	_____	_____